a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers

Immunexpress is a pioneer in the analysis of the immune system to rapidly detect sepsis. This technology uses gene expression in the blood with a specific algorithm to detect a patient’s immune response to a pathogen, rather than the traditional approach of trying to identify a causative pathogen, which represents a paradigm shift in sepsis diagnosis. The company’s mission is to develop diagnostic technologies to help clinicians and patients to fight this life-threatening disease. Immunexpress’ offices are in Seattle, Washington.

View website

Why we invested in Immunexpress

Having worked in the anti-infective space for years, we know that sepsis is one of the biggest killers globally. Rapid diagnosis in sepsis is key to effective management of patients, and Immunexpress’ approach of measuring the host-response on a quick sample-to-result platform is a game-changer.

Are you also an entrepreneur seeking funding?

Discover how we can help you bring your ambition to life

Contact us

Company News

All News

Press Releases

All Press Releases